FINANCIAL INFORMATION CONCERNING THE GROUP’S ASSETS AND LIABILITIES, FINANCIAL POSITIONAND PROFITS AND LOSSES 20 The Group does not hold any short-term investment and all of its an additional €5.2 million in gross proceeds, and the Company cash balances are cash at hand deposits with high-credit quality issued 655,859 ordinary shares with a nominal value of €0.025 financial institutions. and a share premium of €7.975 per share. Note 9: Capital On June 27, 2017, the Company operated a capital increase whose gross proceeds amounted to €22.5 million, by means of 9.1 Share capital issued a private placement reserved to a category of persons, U.S. and The share capital as of December 31, 2017 amounts to European institutional investors specialized in healthcare and €605,855.58. It is divided into 24,234,223 ful ly authorized, biotechnology. The majority of the new shares were al located subscribed and paid-up ordinary shares with a nominal value of to U.S. investors. This increase corresponds to 3,750,000 new €0.025. shares, par value €0.025 each. On July 13, 2016, the Company completed its Initial Public The 24,234,223 outstanding shares does not include BSA, BCE, Offering (IPO) on Euronext Paris, raising €40.0 million in gross AGA and SO. BSA are granted to investors and other individual proceeds, and the Company issued 5,000,000 ordinary shares non-employees, BCE are granted to employees only, AGA are with a nominal value of €0.025 and a share premium of €7.975 granted to employees and / or executives and SO are granted to per share. U.S.-subsidiary employees. On August 10, 2016, the Company partly exercised its The table below shows the changes occurred in the share capital overallotment option as part of its IPO on Euronext Paris, raising during the last two periods: In thousands of euros, except for number of shares Share Capital Share premium Number of shares Balance as of January 1, 2016 340 49,796 13,609,122 Capital increase by issuance of ordinary shares 141 45,109 5,655,859 Less cost of issuance of shares — (3,807) — Issue of shares upon exercise of subscription warrants (1) 4 133 144,720 Total as of December 31, 2016 485 91,230 19,409,701 Balance as of January 1, 2017 485 91,230 19,409,701 Capital increase by issuance of ordinary shares 94 22,406 3,750,000 Less cost of issuance of shares — (1,726) — Issue of shares upon exercise of subscription warrants (1) 27 230 1,074,522 Total as of December 31, 2017 606 112,140 24,234,223 (1) The share premium includes the subscription price of non-employee warrants and the exercise price in excess of the share nominal value for employee and non- employee warrants. 198– GENSIGHT BIOLOGICS – 2017 Registration Document